References

1. Truedsson L, Baskin B, Pan Q, et al. Genetics of IgA deficiency. Apmis 1995;103:833-842.

2. Smith CI, Baskin B, Pattersson E, Hammarstrom L, Islam KB. In vivo switching: identification of germline transcripts for human IgA. Adv Exp Med Biol 1995:9-13.

3. Nikolova EB, Tomana M, Russell MW. All forms of human IgA antibodies bound to antigen interfere with complement (C3) fixation induced by IgG or by antigen alone. Scand J Immunol 1994;39:275-280.

4. Lycke N. T cell and cytokine regulation of the IgA response [in process citation]. Chem Immunol 1998;71:209-234.

5. Kjerrulf M, Grdic D, Kopf M, Lycke N. Induction of gut mucosal immune responses: importance of genetic background and Thl/Th2 cross-regulation. Scand J Immunol 1998;47:401^107.

6. Yan D, H. R. Zhou, et al. Role of macrophages in elevated IgA and IL-6 production by Peyer's patch cultures following acute oral vomitoxin exposure. Toxicol Appl Pharmacol 1998;148:261-73.

Fayette J, Dubois B, Vandenabeele S, et al. Human dendritic cells skew isotype switching of CD40-

activated naive B cells towards IgAl and IgA2. J Exp

Med 1997;185:1909-1918.

Burdin N, Rousset F, Banchereau J. B-cell-

derived IL-10: production and function. Methods

1997;11:98-111.

Yamamoto M, Vancott JL, Okahashi N, et al. The role of Thl and Th2 cells for mucosal IgA responses. Ann N Y Acad Sei 1996;778:64-71. Cunningham-Rundles C, Pudifin DJ, Armstrong D, Good RA. Selective IgA deficiency and neoplasia. Vox Sang 1980;38:61-67.

Zenone T, Souquet PJ, Cunningham-Rundles C, Bernard JP. Hodgkin's disease associated with IgA and IgG subclass deficiency. J Int Med 1996;240:99-102.

Fräser KJ, Rankin JG. Selective deficiency of IgA immunoglobulins associated with carcinoma of the stomach. Australas Ann Med 1970;19:165-167. Branco I, da Costa FB, Rodrigues A, Pires FR, Portugal MA, Goncalves MD. [Gastric neoplasm associated with IgA deficiency. Importance of multi-disciplinary care]. Acta Med Port 1993;6:587-592. Bernett A, Allerhand J, Efremides AP, Cle-jan S. Long-term study of gammopathies. Clinically benign cases showing transition to malignant plasmacytomas after long periods of observation. Clin Biochem 1986; 19:244249.

Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am 1997;11:71-87. Advani SH, Dinshaw KA, Nair CN, et al. Immune dysfunction in non-Hodgkin's lymphoma. Cancer 1980;45:2843-2848.

Dammacco F, Miglietta A, Ventura MT, Bonomo L. Defective monocyte chemotactic responsiveness in patients with multiple myeloma and benign monoclonal gammapathy. Clin Exp Immunol 1982;47:481-486.

Amlot PL, Green L. Serum immunoglobulins G, A, M, D and E concentrations in lymphomas. Br J Cancer 1979;40:371-379.

Alsabti EA, Shaheen A. The prognostic value of serum innumoglobulin levels in Hodgkin's disease. Neoplasma 1979;26:329-333. Bettini R, Steidl L, Rapazzini P, Giardina G. Prognostic value of the staging system proposed by Merlini, Waldenstrom and Jayakar for multiple myeloma. Acta Haematol 1983;70:379-385. Bakkus MH, Van Riet I, Van Camp B, Thielemans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Br J Haematol 1994;87:68-74.

22. Berg AR, Weisenburger DD, Linder J, Armitage JO. Lymphoplasmacytic lymphoma. Report of a case with three monoclonal proteins derived from a single neoplastic clone. Cancer 1986;57:1794-1797.

23. Allen SL, Coleman M. Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma. Cancer Invest 1990;8:417-424.

24. Economopoulos T, Pappa V, Panani A, et al. Myelopathies during the course of multiple myeloma. Haematologica 1991;76:289-292.

25. Isaacson PG. Extranodal lymphomas: the MALT concept. Verh Dtsch Ges Pathol 1992;76:14-23.

26. Fischbach W, Böhm S. Primary stomach lymphoma of the MALT type. Diagnosis and therapy. Gastrointestinal lymphoma study group. Leber Magen Darm 1994;24:104, 107-110.

27. Mielke B, Moller P. Histomorphologic and im-munophenotypic spectrum of primary gastro- intestinal B-cell lymphomas. Int J Cancer 1991;47:334-343.

28. Montalban C, Manzanal A, Boixeda D, et al. Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Ann Oncol 1997;8:37-39.

29. Isaacson PG. Gastrointestinal lymphoma. Human Pathol 1994;25:1020-1029.

30. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma [see comments]. N Engl J Med 1991;325:1127-1131.

31. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez Gl, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii [see comments]. N Engl J Med 1991;325:1132-1136.

32. Jaskowski TD, Martins TB, Hill HR, Litwin CM. Immunoglobulin A antibodies to Helicobacter pylori. J Clin Microbiol 1997;35:2999-3000.

33. Aromaa A, Kosunen TU, Knekt P, et al. Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. Am J Epidemiol 1996;144:142-149.

34. Ohshio G, Kudo H, Yoshioka H, et al. Plasma levels of secretory IgA in patients with gastric cancer. J Cancer Res Clin Oncol 1987;113:573-575.

35. Petrelli NJ, Cajucom CC, Rodriguez-Bigas M, Henslee J, Bhargava A. Altered immunoglobulin A (IgA-1) levels in patients with advanced colorectal adenocarcinoma presenting with normal preopera-

tive levels of carcinoembryonic antigen (CEA). Surg Oncol 1993;2:19-23.

Tabbane S, Tabbane F, Cammoun M, Mourali N. Mediterranean lymphomas with alpha heavy chain monoclonal gammopathy. Cancer 1976;38:1989— 1996.

Al-Saleem TI. Evidence of acquired immune deficiencies in Mediterranean lymphoma. A possible aetiological link. Lancet 1978;2:709-712. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma [see comments]. N Engl J Med 1994;330:1267-1271. Al-Mondhiry H. Primary lymphomas of the small intestine: east-west contrast. Am J Hematol 1986;22:89-105.

Alsabti EA, Safo MH, Shaheen A. Lymphocytes subpopulation in normal family members of patients with alpha-chain disease. J Surg Oncol 1979;11:365-374.

Boo K, Cheng S. A morphological and immunohis-tochemical study of plasma cell proliferative lesions. Malays J Pathol 1992;14:45-48. Asselah F, Slavin G, Sowter G, Asselah H. Immuno-proliferative small intestinal disease in Algerians. I. Light microscopic and immunochemical studies. Cancer 1983;52:227-237.

Colombel JF, Rambaud JC, Vaerman JP, et al. Massive plasma cell infiltration of the digestive tract. Secretory component as the rate-limiting factor of immunoglobulin secretion in external fluids. Gastroenterology 1988;95:1106-1113. Zinzani PL, Magagnoli M, Pagliani G, et al. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients. Haematologica 1997;82:305-308.

Gisbertz IA, Schouten HC, Bot FJ, Arends JW. Cell turnover parameters in small and large cell varieties of primary intestinal non-Hodgkin's lymphoma. Cancer 1998;83:158-165. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996 [see comments]. CA Cancer J Clin 1996;46:5-27.

Brown AM, Lally ET, Frankel A, Harwick R, Davis LW, Rominger CJ. The association of the IGA levels of serum and whole saliva with the progression of oral cancer. Cancer 1975;35:1154—1162. Henle G, Henle W. Serum IgA antibodies of Epstein-Barr virus (EBV)-related antigens. A new feature of nasopharyngeal carcinoma. Bibl Haematol 1975:322-325.

Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976;17:1-7.

50. Veltri RW, Rodman SM, Maxim PE, Baseler MW, Sprinkle PM. Immune complexes, serum proteins, cell-mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck. Cancer 1986;57:2295-2308.

51. Hollyfield ND, Smith FG, Falkler WA, Jr., Thut PD. IgA concentrations in parotid saliva of alcoholics and head and neck cancer patients. J Baltimore Coll Dent Surg 1980;33:1-4.

52. Vinzenz K, Pavelka R, Schonthal E, Zekert F. Serum immunoglobulin levels in patients with head and neck cancer (IgE, IgA, IgM, IgG). Oncology 1986;43:316-322.

53. Susal C, Maier H, Lorenz K, Opelz G. Association of IgA-anti-Fab autoantibodies with disease stage in head-and-neck cancer. Int J Cancer 1994;57:47-50.

54. Aziz M, Akhtar S, Malik A. Evaluation of cellmediated immunity and circulating immune complexes as prognostic indicators in cancer patients. Cancer Detect Prev 1998;22:87-99.

55. Aziz M, Das TK, Rattan A. Role of circulating immune complexes in prognostic evaluation and management of genitourinary cancer patients. Indian J Cancer 1997;34:111-120.

56. Das TK, Aziz M, Rattan A, Sherwani R. Prognostic significance of circulating immune complexes in malignant tumours of head and neck. J Indian Med Assoc 1995;93:3-7.

57. Baseler MW, Maxim PE, Veltri RW. Circulating IgA immune complexes in head and neck cancer, nasopharyngeal carcinoma, lung cancer, and colon cancer. Cancer 1987;59:1727-1731.

58. Susal C, Daniel V, Doerr C, Zimmermann R, Huth-Kuhne A, Opelz G. IgA-anti-Fab autoantibodies and disease progression in AIDS. Immunol Lett 1993;36:27-30.

59. Lorenz KJ, Susal C, Opelz G, Maier H. Relationship between progression of disease and immunoglobulin A-anti- Fab-/F(ab')2 autoantibodies in patients with head and neck cancer. Otolaryngol Head Neck Surg 1998;118:130-136.

60. Schantz SP, Weber RS, Carey TE. Growth and progression of head and neck cancer: a report of the Upper Aerodigestive Cancer Task Force Workshop. Head Neck Surg 1988;10:179-186.

61. Schantz SP, Liu FJ, Taylor D, Beddingfield N, Weber RS. The relationship of circulating IgA to cellular immunity in head and neck cancer patients. Laryngoscope 1988;98:671-678.

62. Prehn RT, Prehn LM. The autoimmune nature of cancer. Cancer Res 1987;47:927-932.

63. Susal C, Daniel V, Opelz G. Does AIDS emerge from a disequilibrium between two complementary groups of molecules that mimic MHC? Immunol Today 1996;17:114-119.

64. Samayoa EA, McDuffie FC, Nelson AM, Go VL, Luthra HS, Brumfield HW. Immunoglobulin complexes in sera of patients with malignancy. Int J Cancer 1977;19:12-17.

65. Schantz SP, Savage HE, Lee NK. Head and neck tumor immunology. II. Humoral immunity. Cancer Treat Res 1990;52:243-263.

66. Bugis SP, Lotzova E, Savage HE, et al. Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer. Cancer Immunol Immunother 1990;31:176-181.

67. Pedersen BK, Thomsen BS, Nielsen H. Inhibition of natural killer cell activity by antigen-antibody complexes. Allergy 1986;41:568-574.

68. Foong YT, Cheng HM, Sam CK, Dillner J, Hinderer W, Prasad U. Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 1990;45:1061— 1064.

69. Tsavaris N, Tsigalakis D, Bobota A, et al. Prognostic value of serum levels of immunoglobulins (IgA, IgM, IgG, IgE) in patients with colorectal cancer. Eur J Surg Oncol 1992;18:31-36.

70. Saito T, Kuwahara A, Kinoshita T, et al. Increases in immunoglobulin and complement in patients with esophageal or gastric cancer. Surg Today 1992;22:537-542.

71. Gminski J, Mykala-Ciesla J, Machalski M, Drozdz M, Najda J. Immunoglobulins and complement components levels in patients with lung cancer. Rom J Int Med 1992;30:39-44.

72. Rossel M, Brambilla E, Billaud M, et al. Nonspecific increased serum levels of secretory component in lung tumors: relationship to the gene expression of the transmembrane receptor form. Am J Respir Cell Mol Biol 1993;9:341-346.

73. Pucci A, Clancy RL, Doe WF. Increased circulating T alpha lymphocyte population in bronchogenic and colonic carcinoma. Clin Exp Immunol 1981 ;46:130-133.

74. Menge AC, Mestecky J. Surface expression of secretory component and HLA class II DR antigen on glandular epithelial cells from human endometrium and two endometrial adenocarcinoma cell lines. J Clin Immunol 1993;13:259-264.

75. Lee YS, Raju GC. Expression of IgA and secretory component in the normal and in adenocarcinomas of Fallopian tube, endometrium and endocervix. Histopathology 1988;13:67-78.

76. Kvale D, Rognum TO, Thorud E, Fossa SD, Ro JS, Brandtzaeg P. Circulating secretory component in breast neoplasms. J Clin Pathol 1987;40:621-625.

77. Chagnaud JL, Faiderbe S, Geffard M. Identification and immunochemical characterization of IgA in sera of patients with mammary tumors. Int J Cancer 1992;50:395-401.

78. Heino P, Goldman S, Lagerstedt U, Dillner J. Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma. Int J Cancer 1993;53:377-381.

79. Gupta SC, Agarwal J, Singh PA, Mehdiratta NK, Keswani NK. A sequential study of humoral factors in ovarian neoplasms. Indian J Pathol Microbiol 1994;37:319-326.

80. Gahankari DR, Golhar KB. An evaluation of serum and tissue bound immunoglobulins in prostatic diseases. J Postgrad Med 1993;39:63-67.

81. Veress B, Gabrielsson N, Granqvist S, Billing H. Mixed colorectal polyps. An immunohistologic and mucin-histochemical study. Scand J Gastroenterol 1991;26:1049-1056.

82. Nakao S, Terano M, Yamashita J, Handa H. [Serum immunoglobulin (IgG, IgM, IgA) levels in patients with primary brain tumors (author's transl)]. No To Shinkei 1977;29:1005-1009.

83. Dawani K, Tayyab M. Immunoglobulin classes G,A,M in brain tumours. JPMA J Pak Med Assoc 1992;42:157-158.

84. Reeves WC, Brinton LA, Garcia M, et al. Human papillomavirus infection and cervical cancer in Latin America. N Engl J Med 1989;320:1437-1441.

85. Reeves WC, Rawls WE, Brinton LA. Epidemiology of genital papillomaviruses and cervical cancer. Rev Infect Dis 1989;11:426-439.

86. Mann VM, de Lao SL, Brenes M, et al. Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Res 1990;50:7815-7819.

87. Lehtinen M, Leminen A, Kuoppala T, et al. Pre- and posttreatment serum antibody responses to HPV 16 E2 and HSV 2ICP8 proteins in women with cervical carcinoma. J Med Virol 1992;37:180-186.

88. Casamassima A, Marinaccio L. Cervical smear total IgA in adenomatous polyp, dysplasia and carcinoma of the cervix. Anticancer Res 1992;12:1315-1318.

89. Se Thoe SY, Wong KK, Pathmanathan R, Sam CK, Cheng HM, Prasad U. Elevated secretory IgA antibodies to Epstein-Barr virus (EBV) and presence of EBV DNA and EBV receptors in patients with cervical carcinoma. Gynecol Oncol 1993;50:168-172.

90. Sasagawa T, Inoue M, Lehtinen M, et al. Serological responses to human papillomavirus type 6

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment